| |
[摘要]：The targeting of autologous vaccines toward antigen presenting cells (APCs) via the in vivo complexation between anti alpha-Gal (anti-Gal) antibodies and alpha-Gal antigens presents a promising cancer immunotherapy with enhanced immunogenicity. This strategy takes advantage of the ubiquitous anti-Gal antibody in human serum. In contrast to the alpha-Gal epitope, the recent identification of high titers of anti-L-rhamnose, (anti-Rha) antibodies in humans reveals a new approach toward immunotherapy employing L-rhamnose (Rha) monosaccharides. In order to evaluate this simple antigen in preclinical applications, we have synthesized Rha-conjugated immunogens and successfully, induced high titers of anti-Rha antibodies in wildtype mice. Moreover, our studies demonstrate for the first time that wildtype mice could replace alpha 1,3galactosyltransferase knockout (alpha 1,3GT KO) mice in such antigen/antibody-mediated vaccine design when developing cancer immunotherapies. |
|
